AC Immune (ACIU) has released an update.
AC Immune has entered into an exclusive partnership with Takeda to develop and potentially commercialize an innovative Alzheimer’s treatment, ACI-24.060, which has shown promise in delaying the disease’s progression. The deal includes an upfront payment of $100 million to AC Immune, with future milestones that could total an additional $2.1 billion, plus tiered royalties on sales post-commercialization.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
